Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

Pharmaceuticals

The cost of prescription drugs has never been higher, and pharmaceutical companies have never spent more persuading consumers that they need drugs they've never heard of for illnesses they didn't know they had. Drug companies are also spending millions defending patents and persuading the FDA to approve new drugs ever faster. Meanwhile, developing countries go without desperately needed drugs because pharmaceutical companies fear that lowering prices for the neediest is a slippery slope. Big Pharma says high prices fund research and innovation.


Drugs Tested By GVK Biosciences Banned From European Union
by Pratap ChatterjeeCorpWatch Blog
July 27th, 2015
Hundreds of drugs tested in India have been banned from sale in the European Union after French inspectors found flaws in clinical trials conducted by GVK Biosciences, a company based in Hyderabad. The Indian government has threatened to take legal action against the ban under international trade rules.

DaVita Pays $895 Million To Settle Kidney Treatment Fraud Claims
by Richard SmallteacherCorpWatch Blog
May 14th, 2015
DaVita, a company that provides health care to patients with kidney problems, has agreed to pay $495 million to settle whistleblower complaints that the company conspired to overcharge the U.S. government. This is in addition to the $400 million that the company had to pay out last year.

Actavis Sued To Stop Forced Switch To New Alzheimer's Drug
by Richard SmallteacherCorpWatch Blog
September 16th, 2014
Actavis, the world's third-largest generic drug manufacturer, has been sued by New York state to prevent it from forcing patients to take a new version of a popular Alzheimer's drug. The company is attempting to hook patients on an extended release version before its U.S. patent expires next year.

Gilead Sciences Under Investigation for Over Charging for Hepatitis C Pill
by Pratap ChatterjeeCorpWatch Blog
July 21st, 2014
Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

Big Pharma Abandons New Tuberculosis Drug Research
by Fatima HansiaCorpWatch Blog
April 1st, 2014
Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people.

Bayer CEO Says Drugs Developed For “Western Patients Who Can Afford It”
by Pratap ChatterjeeCorpWatch Blog
February 3rd, 2014
Bayer, the German pharmaceutical giant, is in hot water after CEO Marijn Dekkers told a Financial Times conference that the company designed medicines “for western patients who can afford it” not for the “Indian market.” The company has been critical of the Indian governments efforts to make cheap generic drugs available locally.

Bumper Year for Corporate Donations Reveals Profit Motives
by Rick CohenCorpWatch Blog
September 10th, 2013
U.S. corporations gave away $18.15 billion in charitable donations in 2012 – a combination of cash, grants, and in-kind goods - up 12.2 percent in nominal terms over the previous year. A closer look reveals profit motives, notably for pharmaceutical companies and retail chain Wal-Mart.

GlaxoSmithKline Alleged to Pay Bribes in China
by Pratap ChatterjeeCorpWatch Blog
July 15th, 2013
GlaxoSmithKline (GSK) has been accused of bribing doctors in China in order to boost sales. Chinese government officials say they have uncovered evidence of a bribery scheme involving 700 travel agencies who were used to funnel as much as three billion yuan ($480 million) in payments.

Myriad Loses Patent to Breast Cancer Genetic Test
by Richard SmallteacherCorpWatch Blog
June 13th, 2013
Myriad Genetics has lost its right to be the exclusive U.S. commercial provider of genetic screening tests for breast cancer or ovarian cancer. The American Civil Liberties Union (ACLU), which sued the company, claimed that the patent would limit scientific research as well as health care options for women.

Ranbaxy Pays $500 Million Fine for Selling Bad Batches of Generic Medicines
by Pratap ChatterjeeCorpWatch Blog
May 14th, 2013
Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has paid a $500 million fine and pled guilty to selling adulterated drugs manufactured in India. The settlement comes 16 months after the company signed an agreement with U.S. authorities to change its ways.

Displaying 1-10 of 28  
Next >> 
Last Page » 
« Show Complete List »